Navigation Links
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Date:2/16/2012

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

"Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm's pipeline," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932."

"We have been highly impressed with the depth of Debiopharm's development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012," said Dan Passeri, Curis President and Chief Executive Officer. "Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future."

About the Phase I Clinical Trial

Debiopharm initiated a Phase I clinical trial in April 2010 that was designed to evaluate the maximum tolerated dose and safety of Debio 0932. The first part of the study (Phase Ia), an open-label,
'/>"/>

SOURCE The Debiopharm Group and Curis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
2. Continuity as Debiopharm Group™ Management Moves Forward
3. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
4. Debiopharm Group™ and Aurigene Nominate Development Candidate
5. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
6. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
7. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
11. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- An intensive effort to sterilize ... animal shelter in Florida and euthanized, a new study reveals. ... to slow their intake into animal control," Dr. Julie Levy, ... College of Veterinary Medicine, said in a university news release. ... making a big impact," she explained, "so we wanted to ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
(Date:8/22/2014)... again attained the distinguished Magnet hospital designation by ... Program. Considered the gold standard for nursing excellence, ... and professionalism. It is the top international credential ... redesignate Newport Hospital was based on the hospital,s ... practice. , "It is a privilege for us ...
(Date:8/22/2014)... (HealthDay News) -- People who use reduced-nicotine cigarettes don,t ... of nicotine, according to a new study. This ... smokers, the researchers say. The month-long study included ... regular cigarettes with nicotine emission levels of 1.2 milligrams ... to reduced-nicotine cigarettes for the next three weeks. ...
Breaking Medicine News(10 mins):Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Neutering Project Curbed Feral Cat Population 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... chief Commissioner Lester Crawford prevented two senior officials// from deciding ... which is a 'morning after' pill. ,These statements ... for Reproductive Rights. Dr. Steven Galson, director of the FDA's ... thing of approving the action to sell Plan B as ...
... The Schizophrenia Fellowship was announced by the greater Southern Area ... family who are unable to support// patients affected with the ... family sensitive mental health program. It would receive about $2 ... Dr Murray Wright, a director of clinical operations mental health, ...
... Women's Hospital (RBWH), Sydney struggles with an outbreak of ... were found with a bacterium called carbapenem ... ,To prevent the spread, 12 patients from burns unit ... shifted to Sydney hospital and some to Brisbane's Princess ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... of commonly used cholesterol-lowering drugs, used by patients ... anti-arrhythmic effect. Scientists with the ... committee evaluated about 458 sudden cardiac deaths with ... of Statin therapy. Among these about, 229 patients ...
... who tried just one cigarette are twice as likely as those ... 3 years it was proved true by another study. ... children trying even one cigarette. In a study with 2000 teens, ... 15-year olds have smoked a cigarette. From about 36 London schools ...
Cached Medicine News:
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: